Hepatocyte Matrix Implant Study Indonesia (HMIIndo)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01335568|
Recruitment Status : Unknown
Verified April 2011 by Baermed.
Recruitment status was: Recruiting
First Posted : April 14, 2011
Last Update Posted : April 14, 2011
This clinical investigation of the hepatocyte matrix implant is an evaluation blinded non-randomized and monocentric pilot study of Phase I, which is conducted as a therapeutic investigation. Randomization is not possible due to ethical and practical reasons. This study has already been approved in Switzerland and has been adapted to Indonesian Law and disease.
This new treatment procedure has already been successfully used on the basis of compassionate use in Germany. The hepatocyte matrix implant is a new patented procedure consisting of bio-matrix technology. A formaldehyde-free special matrix consisting of self-dissolving polymers is applied as a carrier substance and is cultivated with human autologous cells using a special technique. Clinically the bio artificial liver replacement tissue for patients with end-stage hepatic disease has been developed as a first application. In this procedure autologous hepatocytic tissue and pancreatic tissue is removed (liver resection and pancreatic biopsy) from the patient in a first surgical procedure. The tissue is sent to a specialized Cell Culture Laboratory. The laboratory is GMP certified for this procedure. The cells are processed according to SOPs in a special perfusion procedure and prepared on several platelets of matrices (platelets of 20 mm diameter and 4mm thickness). After completion of the laboratory process the bio tissues are implanted into the mesentery of the small intestine during a second operation. The cells are growing controlled on the matrix, take on the capillaries of the patient and thus connect to the blood circulation. The implanted cells multiply by a specific factor and independently take over the metabolic function of the original liver after two to four weeks. In the following process the carrier matrix dissolves completely and implanted cells develop into liver cell tissue.
|Condition or disease||Intervention/treatment||Phase|
|Liver Cirrhosis Liver Insufficiency Chronic Liver Disease||Procedure: Hepatocyte Matrix Implant||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Intracorporeal Autologous Hepatocyte Matrix Implant: A New Tissue Engineering Procedure for Treatment of Hepatic Disease|
|Study Start Date :||April 2011|
|Estimated Primary Completion Date :||December 2011|
|Estimated Study Completion Date :||December 2012|
chronic liver insufficiency, cirrhosis
Procedure: Hepatocyte Matrix Implant
Open surgical procedure with biopsy of liver tissue and pancreatic tissue for proceeding in institutional GMP laboratory. Implantation of autologous hepatocytes and islet cells on scaffolds into the small bowel mesentery. Usually 10 to 20 implants are used.
- Evaluation of clinical and laboratory parameters of liver function [ Time Frame: 6 months ]Evaluation of clinical parameters MELD, CHILD, Asictes, portal hypertension in comparison of values measured 3 and 6 months before operation Evaluation of laboratory parameters Bilirubin, ASAT, ALAT, alkaline phosphatase, cholinesterase, albumin, total protein
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01335568
|Contact: Suryadi The, Dr, MD||+62 firstname.lastname@example.org|
|Contact: Hans U Baer, Prof MD||+41 387 30 email@example.com|
|R.S. Gading Pluit||Recruiting|
|Jakarta, Indonesia, 14250|
|Sub-Investigator: Suryadi The, MD|
|Principal Investigator:||Hans U Baer, Prof, MD||Baermed, RS Gading Pluit, UNTAR|